PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25429617-5	2014	We further showed that the combination of citreoviridin and the 26S proteasome inhibitor bortezomib could improve the anticancer activity by enhancing ER stress, by ameliorating citreoviridin-caused cyclin D3 compensation, and by contributing to CDK1 deactivation and PCNA downregulation.	Bortezomib	89-99	cyclin dependent kinase 1	Homo sapiens	246-250	
20367638-6	2010	A further analysis of cell cycle-related proteins revealed that bortezomib increased the expression levels of cyclin B1, the cdc2/cyclin B complex, and the phosphorylation of all T14, Y15, and T161 residues on cdc2.	Bortezomib	64-74	cyclin dependent kinase 1	Homo sapiens	125-129	
20367638-6	2010	A further analysis of cell cycle-related proteins revealed that bortezomib increased the expression levels of cyclin B1, the cdc2/cyclin B complex, and the phosphorylation of all T14, Y15, and T161 residues on cdc2.	Bortezomib	64-74	cyclin dependent kinase 1	Homo sapiens	210-214	
20367638-7	2010	Bortezomib also increased the ubiquitination of cyclin B1 and wee1, but inhibited the kinase activity of the cdc2/cyclin B complex.	Bortezomib	0-10	cyclin dependent kinase 1	Homo sapiens	109-113	
16928825-4	2006	The effects of bortezomib were associated with accumulation of p21 and mimicked by chemical CDK inhibitors or by transfecting cells with a small interfering RNA construct specific for CDK1.	Bortezomib	15-25	cyclin dependent kinase 1	Homo sapiens	184-188	
16928825-6	2006	Together, our data show that bortezomib interferes with docetaxel-induced apoptosis via a p21-dependent mechanism that is associated with CDK1 inhibition.	Bortezomib	29-39	cyclin dependent kinase 1	Homo sapiens	138-142	
28055975-7	2017	BTZ stabilized p21, CDC2, and cyclin B in RRCL and in primary tumor cells.	Bortezomib	0-3	cyclin dependent kinase 1	Homo sapiens	20-24	
22552540-8	2012	Investigation of G2-M phase-related cell cycle proteins involved in the response to bortezomib revealed that the ataxia telangiectasia mutated (ATM)-cell cycle checkpoint kinase 1 (CHK1) pathway, but not ATM and Rad3-related (ATR), was activated, resulting in the inactivation of cdc2.	Bortezomib	84-94	cyclin dependent kinase 1	Homo sapiens	280-284	
19039521-7	2009	Bortezomib alone or in combination with taxol induced a cell cycle arrest within the S phase, and downregulation of cdk1, a cyclin-dependent kinase that is necessary for the entry into the M phase.	Bortezomib	0-10	cyclin dependent kinase 1	Homo sapiens	116-120	
19074855-8	2008	These cells were killed by bortezomib, albeit at higher pharmacologic concentrations, via mitotic catastrophe-a mitotic cell death associated with M-phase arrest, cyclin B1 accumulation, and increased CDC2/CDK1 activity.	Bortezomib	27-37	cyclin dependent kinase 1	Homo sapiens	201-205	
19074855-8	2008	These cells were killed by bortezomib, albeit at higher pharmacologic concentrations, via mitotic catastrophe-a mitotic cell death associated with M-phase arrest, cyclin B1 accumulation, and increased CDC2/CDK1 activity.	Bortezomib	27-37	cyclin dependent kinase 1	Homo sapiens	206-210